Price
3,361.1
-7.42%52W Range
Market Cap
₹3,487.54 Cr
Traded: ₹38.73 Cr (1.11%) 0.0x
Free Float: ₹763.77 Cr (5.07% of FF traded)
Volume · 60D trend
1.14 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +26.0% | +27.0% | +18.0% | -- | -- | Stable |
| Return | +64.0% | +56.0% | +102.0% | +177.0% | -- | Accelerating |
| Sales | +21.0% | +14.0% | +26.0% | -- | +38.0% | Accelerating |
| Profit | +44.0% | +35.0% | +29.0% | -- | +88.0% | Stable |
Quarterly Results
Mar 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 162 | 157 | 123 | 111 | 111 | 116 | 84 | 90 | 80 | 92 | 78 | 70 | 67 | 69 |
| Expenses | 121 | 118 | 93 | 86 | 87 | 90 | 67 | 70 | 63 | 71 | 61 | 54 | 54 | 57 |
| Operating Profit | 41 | 39 | 30 | 25 | 24 | 26 | 18 | 20 | 17 | 21 | 17 | 15 | 14 | 11 |
| OPM % | 25.0% | 25.0% | 24.0% | 23.0% | 22.0% | 22.0% | 21.0% | 22.0% | 22.0% | 22.0% | 21.0% | 22.0% | 20.0% | 17.0% |
| Other Income | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | -7 | 1 | 0 | 0 | -15 |
| Interest | 3 | 3 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 4 |
| Profit Before Tax | 34 | 32 | 22 | 18 | 17 | 19 | 11 | 13 | 11 | 6 | 10 | 8 | 7 | -10 |
| Tax % | 25.0% | 20.0% | 28.0% | 23.0% | 30.0% | 24.0% | 25.0% | 33.0% | 25.0% | 29.0% | 21.0% | 24.0% | 25.0% | -24.0% |
| Net Profit | 26 | 25 | 16 | 14 | 12 | 14 | 9 | 8 | 8 | 4 | 8 | 6 | 5 | -7 |
| Exceptional Items | -- | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | -7 | 0 | 0 | 0 | -17 |
| EPS (Rs) | 24.7 | 24.4 | 15.4 | 13.6 | 11.5 | 14.0 | 8.2 | 8.2 | 8.1 | 4.2 | 7.4 | 6.0 | 5.2 | -7.1 |
| Sales Growth (YoY) | 46.0% | 35.3% | 46.4% | 23.3% | 38.8% | 26.1% | 7.7% | 28.6% | 19.4% | 33.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 3.2% | 27.6% | 10.8% | 0.0% | -4.3% | 38.1% | -6.7% | 12.5% | -13.0% | 17.9% | 11.4% | 4.5% | -2.9% | -- |
| OP Growth (YoY) | 70.8% | 50.0% | 66.7% | 25.0% | 41.2% | 23.8% | 5.9% | 33.3% | 21.4% | 90.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | 5.1% | 30.0% | 20.0% | 4.2% | -7.7% | 44.4% | -10.0% | 17.6% | -19.0% | 23.5% | 13.3% | 7.1% | 27.3% | -- |
| Profit Growth (YoY) | -- | 75.0% | 95.0% | 67.0% | 43.0% | 49.0% | 11.0% | 36.0% | 54.0% | 9.0% | 8.0% | -34.0% | -49.0% | -15.0% |
| EPS Growth (YoY) | 114.7% | 74.6% | 87.7% | 66.8% | 42.7% | 232.4% | 10.9% | 35.8% | 54.4% | 159.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 1.3% | 58.0% | 13.4% | 18.4% | -17.6% | 69.8% | 0.7% | 1.2% | 91.9% | -43.3% | 23.3% | 15.1% | 173.4% | -- |
| OP Margin | 25.3% | 24.8% | 24.4% | 22.5% | 21.6% | 22.4% | 21.4% | 22.2% | 21.3% | 22.8% | 21.8% | 21.4% | 20.9% | 15.9% |
| Net Margin | 16.1% | 15.9% | 13.0% | 12.6% | 10.8% | 12.1% | 10.7% | 8.9% | 10.0% | 4.3% | 10.3% | 8.6% | 7.5% | -10.1% |
| Material Cost % | -- | 55.0% | 48.0% | 49.0% | 52.0% | 53.0% | 46.0% | 49.0% | 49.0% | 50.0% | 51.0% | 49.0% | 49.0% | 50.0% |
| Employee Cost % | -- | 9.0% | 12.0% | 12.0% | 11.0% | 11.0% | 13.0% | 11.0% | 12.0% | 10.0% | 10.0% | 11.0% | 11.0% | 11.0% |
| P/S | 6.31 | 5.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 43.03 | 40.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 10.54 | 8.19 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.
Newspaper Publication of Notice of 43rd Annual General Meeting.
Outcome of Investors/Analysts Meeting held on August 10, 2026
Transcript of Earnings Conference Call - Q1FY27
Transcript of Earnings Conference Call - Q1FY27
Investor Presentation for quarter ended June 30, 2026.
Financial Results for Quarter Ended June 30, 2026.
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015
NOTICE OF 43RD AGM IS ENCLOSED
Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('' Listing Regulations''), please find attached herewith the Annual Report of the Company for the FY ....
This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors ....
Intimation of 43rd AGM
Intimation of Book Closure.
Kwality Pharmaceuticals receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30-06-2026.
Intimation of Closure of Trading Window
Resignation of Mr. Kartik Kapur, Independent Director of the Company.
Appointment of Mr. Swanith Kapoor as Additional (Non-Executive, Independent) Director and Resignation of Mr. Kartik Kapur, Independent Director of the Company.
Annual Secretarial Compliance Report for the year ended 31-03-2026 is enclosed herewith
Audio recording of quarterly earning conference call
Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.
Transcript of Earning Conference Call of Q4FY2026.
Audited Financial Results for the quarter and year ended 31st March, 2026.
Investor Presentation for the quarter and year ended 31st March, 2026.
Audited Financial Results for the quarter and year ended 31st March, 2026
Intimation of Analysts/Investors Conference Call to be held on May 19, 2026 at 5:00 P.M. to discuss Q4 FY26 financial results.
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
Intimation of Revision in Credit Rating
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for quarter ended March 31, 2026
outcome of postal ballot is attached herewith
Scrutinizer Report for Postal Ballot
Intimation of Closure of Trading Window
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Updation on Bioequivalence (BE) Program- Successful Completion of Phase 1 by ....
Intimation of Schedule of Analysts/Institutional Investors Meeting to be held on March 12, 2026 through an in-person Site Visit.
Intimation of Schedule of Analysts/ Institutional Investors Meeting to be held on March 10, 2026 at 4:00 P.M.
Newspaper Publication of Postal Ballot Notice and E-voting Information
Postal Ballot Notice Dtd February 21, 2026
Newspaper Publication of Unaudited Financial Results for the Quarter Ended December 31, 2025
Outcome of Analyst Meeting.
Outcome of Investor/Analysts Meeting
Investor Presentation of Financial Results
Approval of Unaudited Financial Results for the quarter and nine months ended 31-12-2025
Approval of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025
Intimation of Schedule of Investors/ Analysts Meeting to be held on Friday, 13th February, 2026 at 4:30 p.m.
Revised Intimation for Cessation of Independent Directors on completion of their Tenure.
Cessation of Independent Directors upon completion of tenure.
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
We wish to inform you that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company, at its meeting held today i.e. on January 28, 2026 has, ....
Appointment of Mr. Bhavesh Mahajan as Additional Independent Director on the Board of the Company
Held by ETFs
1 ETFs hold kpl · sorted by weight
Held by Mutual Funds
1 schemes hold kpl · sorted by weight